Policy corpus

The coverage policies we hold

One row per policy: the contractor that issued it, the effective date CMS published, how many distinct versions of its text we have captured, and the CMS document. Every row links to its source. Nothing here is behind a login. The dated change feed is a different view of the same records.

1,097 local coverage determinations · page 3 of 11

PolicyTitleContractorEffectiveVersions heldSource
L35526B-type Natriuretic Peptide (BNP) TestingNoridian2026-03-051cms.gov ↗
L35986Special Histochemical Stains and Immunohistochemical StainsCGS Administrators2026-03-051cms.gov ↗
L36029Urine Drug TestingCGS Administrators2026-03-051cms.gov ↗
L36902Polysomnography and Other Sleep StudiesCGS Administrators2026-03-051cms.gov ↗
L37575Frequency of HemodialysisCGS Administrators2026-03-051cms.gov ↗
L38268Immune Thrombocytopenia (ITP) TherapyCGS Administrators2026-03-051cms.gov ↗
L38307Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep ApneaCGS Administrators2026-03-051cms.gov ↗
L38335MolDX: Pharmacogenomics TestingNoridian2026-03-051cms.gov ↗
L38613Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart DiseaseNoridian2026-03-051cms.gov ↗
L38705Transurethral Waterjet Ablation of the ProstateNoridian2026-03-051cms.gov ↗
L39396Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell OriginNoridian2026-03-051cms.gov ↗
L39434Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell OriginCGS Administrators2026-03-051cms.gov ↗
L39462Sacroiliac Joint Injections and ProceduresNoridian2026-03-051cms.gov ↗
L39642Intraosseous Basivertebral Nerve AblationNoridian2026-03-051cms.gov ↗
L37421Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorNational Government Services2026-03-011cms.gov ↗
L40168Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)National Government Services2026-03-011cms.gov ↗
L40176Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Noridian2026-03-011cms.gov ↗
L40179Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)CGS Administrators2026-03-011cms.gov ↗
L40189Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Palmetto GBA2026-03-011cms.gov ↗
L40193Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)WPS2026-03-011cms.gov ↗
L34771Immune GlobulinsWPS2026-02-261cms.gov ↗
L35751Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesWPS2026-02-261cms.gov ↗
L35753Non-Invasive Cerebrovascular StudiesWPS2026-02-261cms.gov ↗
L36523MolDX: Biomarkers in Cardiovascular Risk AssessmentWPS2026-02-261cms.gov ↗
L37537Frequency of HemodialysisWPS2026-02-261cms.gov ↗
L38176MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid MalignanciesWPS2026-02-261cms.gov ↗
L35170Botulinum Toxin InjectionsNoridian2026-02-221cms.gov ↗
L35172Botulinum Toxin InjectionsNoridian2026-02-221cms.gov ↗
L39832Botulinum Toxin InjectionsNational Government Services2026-02-221cms.gov ↗
L39836Botulinum Toxin InjectionsPalmetto GBA2026-02-221cms.gov ↗
L39857Botulinum Toxin InjectionsCGS Administrators2026-02-221cms.gov ↗
L38070MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid MalignanciesCGS Administrators2026-02-191cms.gov ↗
L39276MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaCGS Administrators2026-02-191cms.gov ↗
L34410B-type Natriuretic Peptide (BNP) TestingPalmetto GBA2026-02-151cms.gov ↗
L38623Implantable Continuous Glucose Monitors (I-CGM)National Government Services2026-02-091cms.gov ↗
L39226Multiplex Gastrointestinal Pathogen Panel (GPP) Tests for Acute Gastroenteritis (AGE)National Government Services2026-02-091cms.gov ↗
L35160MolDX: Molecular Diagnostic Tests (MDT)Noridian2026-02-051cms.gov ↗
L36335MolDX: NRAS Genetic TestingNoridian2026-02-051cms.gov ↗
L36941MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™)Noridian2026-02-051cms.gov ↗
L37299MolDX: Prometheus® IBD sgi Diagnostic® PolicyNoridian2026-02-051cms.gov ↗
L38119MolDX: Next-Generation Sequencing for Solid TumorsNoridian2026-02-051cms.gov ↗
L38123MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid MalignanciesNoridian2026-02-051cms.gov ↗
L38151MolDX: Pigmented Lesion AssayNoridian2026-02-051cms.gov ↗
L38327MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung CancerNoridian2026-02-051cms.gov ↗
L38339MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized DiseaseNoridian2026-02-051cms.gov ↗
L38351MolDX: Repeat Germline TestingNoridian2026-02-051cms.gov ↗
L38643MolDX: Phenotypic Biomarker Detection from Circulating Tumor CellsNoridian2026-02-051cms.gov ↗
L38814MolDX: Minimal Residual Disease Testing for CancerNoridian2026-02-051cms.gov ↗
L38972MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with CancerNoridian2026-02-051cms.gov ↗
L39001MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification TestingNoridian2026-02-051cms.gov ↗
L39230MolDX: Plasma-Based Genomic Profiling in Solid TumorsNoridian2026-02-051cms.gov ↗
L39682MolDX: Molecular Testing for Risk Stratification of Thyroid NodulesNoridian2026-02-051cms.gov ↗
L39923MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative NeoplasmsNoridian2026-02-051cms.gov ↗
L39948MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin AmyloidosisNoridian2026-02-051cms.gov ↗
L33370NebulizersDME MAC2026-02-011cms.gov ↗
L33945Cerumen (Earwax) RemovalCGS Administrators2026-01-291cms.gov ↗
L33960Cardiovascular Nuclear MedicineCGS Administrators2026-01-291cms.gov ↗
L35761Non-Invasive Peripheral Arterial Vascular StudiesWPS2026-01-291cms.gov ↗
L36690Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower ExtremitiesCGS Administrators2026-01-291cms.gov ↗
L36975Bladder/Urothelial Tumor MarkersCGS Administrators2026-01-291cms.gov ↗
L37254Chiropractic ServicesCGS Administrators2026-01-291cms.gov ↗
L37608MDS FISHCGS Administrators2026-01-291cms.gov ↗
L39713Trigger Point InjectionsWPS2026-01-291cms.gov ↗
L33318Knee OrthosesDME MAC2026-01-251cms.gov ↗
L33999Corneal PachymetryCGS Administrators2026-01-221cms.gov ↗
L34005Colonoscopy/Sigmoidoscopy/ProctosigmoidoscopyCGS Administrators2026-01-221cms.gov ↗
L34008Computerized Corneal TopographyCGS Administrators2026-01-221cms.gov ↗
L34062Dialysis Access MaintenanceCGS Administrators2026-01-221cms.gov ↗
L36155MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)Noridian2026-01-221cms.gov ↗
L36188MolDX: MGMT Promoter Methylation AnalysisNoridian2026-01-221cms.gov ↗
L36358MolDX: Biomarkers in Cardiovascular Risk AssessmentNoridian2026-01-221cms.gov ↗
L36380MolDX: Breast Cancer Assay: Prosigna®Noridian2026-01-221cms.gov ↗
L36551MolDX: HLA-DQB1*06:02 Testing for NarcolepsyNoridian2026-01-221cms.gov ↗
L37070MolDX: DecisionDx-UM (Uveal Melanoma)Noridian2026-01-221cms.gov ↗
L37126Coenzyme Q10 (CoQ10)CGS Administrators2026-01-221cms.gov ↗
L37295MolDX: EndoPredict® Breast Cancer Gene Expression TestNoridian2026-01-221cms.gov ↗
L37750MolDX: Melanoma Risk Stratification Molecular TestingNoridian2026-01-221cms.gov ↗
L37822MolDX: Breast Cancer Index® (BCI) Gene Expression TestNoridian2026-01-221cms.gov ↗
L37887MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic TestNoridian2026-01-221cms.gov ↗
L37897MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung CancerNoridian2026-01-221cms.gov ↗
L38288MolDX: Repeat Germline TestingCGS Administrators2026-01-221cms.gov ↗
L38331MolDX: Blood Product Molecular Antigen TypingNoridian2026-01-221cms.gov ↗
L39005MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate CancerNoridian2026-01-221cms.gov ↗
L39262MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and NeoplasiaNoridian2026-01-221cms.gov ↗
L39373MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaNoridian2026-01-221cms.gov ↗
L39467MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid ArthritisNoridian2026-01-221cms.gov ↗
L39521Positron Emission Tomography (PET) Scan for Inflammation and InfectionCGS Administrators2026-01-221cms.gov ↗
L39589MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell CarcinomaNoridian2026-01-221cms.gov ↗
L39616Urinary Biomarkers for Chronic Pain ManagementCGS Administrators2026-01-221cms.gov ↗
L39678MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following BronchoscopyNoridian2026-01-221cms.gov ↗
L39686MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate CancersNoridian2026-01-221cms.gov ↗
L39944MolDX: Genetic Testing for Heritable Thoracic Aortic DiseaseNoridian2026-01-221cms.gov ↗
L40224Automated Detection and Quantification of Brain MRIsCGS Administrators2026-01-191cms.gov ↗
L37352MolDX: Prometheus IBD sgi Diagnostic® PolicyCGS Administrators2026-01-151cms.gov ↗
L38065MolDX: Plasma-Based Genomic Profiling in Solid TumorsCGS Administrators2026-01-151cms.gov ↗
L33824Immunosuppressive DrugsDME MAC2026-01-011cms.gov ↗
L33826Oral Anticancer DrugsDME MAC2026-01-011cms.gov ↗
L33827Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics)DME MAC2026-01-011cms.gov ↗
L34528Blepharoplasty, Blepharoptosis and Brow LiftWPS2026-01-011cms.gov ↗
L34623Intraoperative Neurophysiological TestingWPS2026-01-011cms.gov ↗

“Versions held” counts distinct captured texts of the policy since capture began; a policy captured once has one. A “—” means the count could not be read on this load, not that none are held. How versions are captured and dated is on Methodology.